Market Trends of MicroRNA Industry
Real-Time Polymerase Chain Reaction Segment is Expected to Witness a Significant Growth in the Market Over the Forecast Period
- The polymerase chain reaction is based on using the ability of DNA polymerase to synthesize a new strand of DNA complementary to the offered template strand. The polymerase chain reaction is widely used to rapidly make millions to billions of copies of a specific DNA sample.
- The factors propelling the growth of real-time polymerase chain reaction are the rising prevalence of chronic diseases, increasing application of polymerase chain reaction in drug development, clinical diagnostics, and rapid technological advancements such as the development of high-performance and superior quantitative PCR (qPCR) and digital PCR (dPCR) systems.
- As per the article published in February 2022 in the MDPI journal, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) is an effective and common method for sensitive and specific analysis of microRNA from biological fluids, such as plasma or serum.
- Similarly, as per the article published in September 2022 in Kargar, quantitative PCR is the most frequently used method of measuring expression levels of microRNA. Also, various technological advancements in PCR systems are widely accepted for the quantification of microRNAs. For instance, as per the article published in June 2022 in PubMed, circulating microRNAs have been suggested as particular illness biomarkers. The current gold standard method for assessing microRNA expression from various sources is quantitative real-time PCR (RT-qPCR).
- Furthermore, government funding for clinical research which also includes PCR-based studies, is expected to drive market growth. For instance, as per the NIH 2022 update, the estimated research funding for clinical research is USD 18.38 billion in 2023. Thus, the increase in research and development in PCR technologies involving the development of microRNA is expected to drive segment growth over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
North America is Expected to Have the Significant Market Share Over the Forecast Period
- North America is expected to hold a significant market share in the studied market due to the increase in incidences of chronic diseases and rising demand for next-generation and microRNA services and applications in drug development.
- Further, the other factors fueling the market growth are the adoption of the latest technology and the established research infrastructure for proteomics and genomics. The rising number of cardiovascular diseases in the region is the key driving factor in the growth of the microRNA market. As per the data from the CARES Report 2021, 97.6% of adults and 2.4% of children were reported with out-of-hospital cardiac arrest in 2021 in the United States.
- In addition, the increasing drug and patent approvals from the FDA in the region are also contributing to the growth of the market. For instance, in December 2021, InteRNA Technologies received Investigational New Drug approval from the United States Food and Drug Administration for its Phase I clinical trial evaluating the lead microRNA candidate, INT-1B3, in patients with advanced solid tumors. This approval enables InteRNA to expand the number of clinical sites and facilitate the enrollment of patients for the dose-expansion part of the trial in the United States.
- Moreover, the presence of key players, such as Illumina Inc., Thermo Fisher Scientific, etc., and an increase in research and development spending by companies to develop innovative and advanced products in the United States are expected to drive regional growth. For instance, in March 2021, DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory from Interpace Biosciences, Inc. Acquisition of this CLIA-certified lab facility significantly expands DiamiR's capabilities to develop and commercialize their microRNA-based tests for early detection, differential diagnosis, prediction of progression and monitoring of brain health and other conditions.
- Thus, the rising number of chronic disease cases, new product launches, and increasing product approvals are likely to increase the growth of the microRNA market in the studied region.
Get Analysis on Important Geographic Markets
Download Sample
